AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • March 8th, 2022 • OptiNose, Inc. • Pharmaceutical preparations • Delaware
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on March 2, 2022, by and between OptiNose US, Inc., a Delaware corporation (“OptiNose US”) and wholly-owned subsidiary of OptiNose, Inc. (the “Parent” and, together with OptiNose US, the “Company”), and Keith A. Goldan (“Executive”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • March 8th, 2022 • OptiNose, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is made as of __________, 201___ by and between OptiNose, Inc., a Delaware corporation (the “Corporation”), in its own name and on behalf of its direct and indirect subsidiaries, and __________________, an individual (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Corporation and Indemnitee covering the subject matter of this Agreement.
RETENTION AGREEMENTRetention Agreement • March 8th, 2022 • OptiNose, Inc. • Pharmaceutical preparations • Pennsylvania
THIS RETENTION AGREEMENT (“Agreement”) is made and entered into between Michael F. Marino (“Executive”) and OptiNose US, Inc. (OptiNose US”), a Delaware corporation and wholly-owned subsidiary of OptiNose, Inc. (the “Parent” and, together with OptiNose US, the “Company”) (all together, the “Parties”), effective as of the date last executed below (the “Effective Date”).
